Viking Therapeutics announced it will present two posters at the 33rd European Congress on Obesity highlighting data from its Phase 2 trial of VK2735, an oral and subcutaneous dual GLP-1/GIP receptor agonist for obesity treatment. The Phase 2 VENTURE-Oral trial showed significant weight loss and good tolerability over 13 weeks. Additionally, Viking shared enrollment details of the ongoing Phase 3 VANQUISH-1 trial targeting adults with obesity or overweight with related health issues. These presentations mark important steps in VK2735's clinical development, with further data expected from the Phase 3 study.
ISS has secured a seven-year contract with West Sussex County Council to deliver around 25,000 nutritious school meals daily to primary schools starting Q3 2026. The contract, valued at about DKK 100 million annually, emphasizes inclusivity and high ...
Roche has introduced the Liver Disease Panel, the first comprehensive set of certified algorithms designed to improve the detection and management of chronic liver disease (CLD). This panel includes LiverPRO, an algorithm that uses routine blood mark...
TGS ASA has secured a large 4D streamer contract offshore Angola, set to begin data acquisition in early July 2026 and last about eight months. This contract strengthens TGS's strategic presence in Africa and ensures vessel utilization into early 202...
argenx, a global immunology company focused on autoimmune diseases, announced its management team will present at two key investor conferences in June: the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Hea...
Capgemini unveiled its 2028 strategic plan focusing on leveraging AI agent technology to drive business transformation for large enterprises. The company aims for a 5.5% to 7.5% annual revenue growth from 2025 to 2028, with about 2 points from merger...
